A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Summary

ASLAN003-003 is a multi-center, Phase IIA study to evalute the efficacy of ASLAN003 in AML patients who are ineligible for standard treatment with an expansion cohort in relapsed/refractory patients, and to determine the appropriate dose of ASLAN003 in combination with azacitidine in older (more than or equal to 60 years) AML patients who have exhausted any approved and available treatment options.

Timeline

Start

2018-01-05

Primary completion

2019-09-11

Completion

2019-12-13

Drugs

Indications